Last 48 quarters of trend data · Healthcare · Diagnostics & Lab Testing
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -60.87 | — | 182.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.50 | 2.82 | 2.37 | 1.28 | 1.99 | 1.31 | 1.29 | 1.80 | 3.03 | 2.79 | 2.66 | 0.63 | 0.65 | 0.51 | 0.69 | 0.79 | 0.42 | 0.42 | 0.40 | 0.64 | 1.67 |
| — | +114.6% | +83.5% | -28.6% | -34.4% | -52.9% | -51.6% | +183.5% | +363.2% | +448.4% | +288.6% | -20.0% | +57.7% | +22.3% | +69.6% | +23.7% | -75.1% | -82.9% | -83.4% | -73.6% | -31.6% | |
| P/B Ratio | 2.34 | 2.95 | 2.43 | 1.16 | 1.81 | 1.18 | 1.10 | 1.36 | 2.31 | 2.06 | 1.91 | 0.43 | 0.43 | 0.33 | 0.42 | 0.45 | 0.23 | 0.21 | 0.19 | 0.28 | 0.76 |
| — | +150.3% | +121.8% | -15.0% | -21.8% | -42.9% | -42.8% | +216.9% | +434.5% | +531.8% | +354.3% | -3.9% | +87.4% | +54.3% | +117.4% | +59.9% | -69.5% | -79.7% | -81.2% | -79.0% | -57.2% | |
| P/FCF | — | — | 40.65 | — | — | 433.12 | 16.69 | — | — | — | 538.46 | — | 9.50 | — | — | — | — | — | — | — | — |
| — | — | +143.5% | — | — | — | -96.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 125.81 | 80.95 | 85.87 | — | 86.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 212.09 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.8% | 46.2% | 45.6% | 43.3% | 39.8% | 42.8% | 42.6% | 43.6% | 44.9% | 44.6% | 44.1% | 41.9% | 43.5% | 41.0% | 40.8% | 39.9% | 41.0% | 38.0% | 35.1% | 32.6% | 36.0% |
| — | +7.8% | +6.9% | -0.6% | -11.4% | -4.0% | -3.3% | +4.0% | +3.4% | +8.8% | +8.1% | +4.9% | +6.1% | +8.0% | +16.0% | +22.4% | +13.8% | -2.5% | -19.3% | -9.3% | -21.1% | |
| Operating Margin | -9.1% | -3.8% | -4.8% | -9.8% | -5.9% | -14.4% | -26.3% | -16.6% | -10.7% | -12.6% | -13.3% | -19.6% | -11.9% | -15.9% | -20.3% | -25.6% | -19.0% | -30.7% | -31.7% | -44.4% | -33.1% |
| — | +73.6% | +81.6% | +41.0% | +45.2% | -13.9% | -96.9% | +15.4% | +10.4% | +20.7% | +34.4% | +23.5% | +37.2% | +48.1% | +35.9% | +42.4% | +42.5% | +6.3% | -72.8% | -239.6% | -852.0% | |
| Net Margin | -14.9% | -3.6% | 1.1% | -9.2% | -5.2% | -14.4% | -24.9% | -15.4% | -8.9% | -10.5% | -11.3% | -17.3% | -9.2% | -12.2% | -16.6% | -22.4% | -16.4% | -28.6% | -28.2% | -42.2% | -33.2% |
| — | +75.0% | +104.5% | +40.6% | +41.7% | -37.0% | -119.4% | +10.9% | +3.3% | +13.5% | +31.6% | +22.8% | +43.7% | +57.4% | +41.3% | +46.8% | +50.8% | -70.6% | -145.3% | -120.3% | -371.4% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -12.4% | -1.0% | 0.3% | -2.1% | -1.2% | -3.2% | -5.2% | -2.9% | -1.7% | -1.9% | -2.0% | -2.9% | -1.5% | -1.9% | -2.5% | -3.1% | -2.3% | -3.6% | -3.3% | -4.5% | -3.7% |
| — | +70.3% | +105.4% | +29.0% | +30.3% | -65.2% | -155.3% | +0.2% | -11.6% | +0.2% | +19.6% | +7.1% | +32.8% | +45.7% | +24.4% | +31.0% | +39.3% | -101.3% | -143.8% | -57.4% | -264.1% | |
| ROA | -7.2% | -0.6% | 0.2% | -1.3% | -0.7% | -2.0% | -3.0% | -1.6% | -0.9% | -1.1% | -1.1% | -1.6% | -0.9% | -1.1% | -1.4% | -1.8% | -1.3% | -2.1% | -1.9% | -2.7% | -2.2% |
| — | +71.8% | +105.5% | +21.0% | +22.7% | -81.8% | -165.2% | +1.8% | -9.6% | +1.8% | +20.6% | +8.7% | +34.3% | +47.2% | +26.7% | +33.2% | +41.3% | -94.1% | -143.6% | -53.4% | -243.8% | |
| ROIC | -4.3% | -0.5% | -0.7% | -1.2% | -0.7% | -1.8% | -3.2% | -1.8% | -1.2% | -1.4% | -1.4% | -1.9% | -1.1% | -1.4% | -1.7% | -2.0% | -1.5% | -2.2% | -2.2% | -2.8% | -2.2% |
| — | +70.6% | +78.7% | +33.1% | +37.8% | -34.7% | -127.6% | +4.1% | -6.2% | +4.7% | +19.8% | +4.0% | +22.5% | +33.7% | +19.8% | +29.2% | +34.0% | -1.2% | -40.8% | -85.5% | -456.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.56 | 0.56 | 0.57 | 0.49 | 0.56 | 0.49 | 0.48 | 0.68 | 0.67 | 0.67 | 0.66 | 0.66 | 0.65 | 0.64 | 0.64 | 0.63 | 0.61 | 0.60 | 0.59 | 0.57 | 0.55 |
| — | +14.6% | +18.4% | -27.6% | -15.8% | -26.7% | -27.2% | +3.4% | +3.3% | +4.4% | +3.9% | +5.2% | +6.1% | +5.9% | +8.7% | +9.8% | +10.7% | +12.0% | +14.5% | -17.7% | +75.1% | |
| Debt / EBITDA | 270.65 | 54.45 | 69.63 | — | 89.89 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.26 | 3.53 | 3.60 | 4.42 | 4.26 | 3.91 | 3.92 | 2.05 | 1.98 | 1.99 | 2.01 | 7.48 | 6.20 | 6.32 | 6.16 | 6.75 | 6.73 | 7.10 | 7.53 | 7.93 | 7.81 |
| — | -9.6% | -8.1% | +115.3% | +115.4% | +96.2% | +94.5% | -72.6% | -68.1% | -68.5% | -67.3% | +10.8% | -7.9% | -11.0% | -18.1% | -14.9% | -13.9% | -7.3% | +3.4% | -43.0% | +27.4% | |
| Quick Ratio | 3.94 | 3.31 | 3.35 | 4.06 | 3.94 | 3.62 | 3.58 | 1.95 | 1.89 | 1.91 | 1.93 | 7.22 | 5.95 | 6.06 | 5.90 | 6.47 | 6.46 | 6.82 | 7.26 | 7.64 | 7.54 |
| — | -8.4% | -6.5% | +108.9% | +108.4% | +89.4% | +84.9% | -73.0% | -68.2% | -68.5% | -67.2% | +11.5% | -8.0% | -11.2% | -18.7% | -15.3% | -14.4% | -8.1% | +2.8% | -43.8% | +31.7% | |
| Interest Coverage | -28.38 | -5.33 | 3.34 | -28.39 | -19.71 | -43.76 | -48.11 | -14.86 | -8.93 | -9.87 | -10.41 | -15.43 | -8.09 | -11.73 | -13.93 | -18.19 | — | -284.06 | -40.50 | -35.46 | -24.90 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NEO stock.
NeoGenomics, Inc.'s current P/E is -60.9x. The average P/E over the last 1 quarters is 182.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
NeoGenomics, Inc.'s current operating margin is -9.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking NeoGenomics, Inc.'s business trajectory between earnings reports.